Ignite Creation Date:
2024-05-05 @ 5:16 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00425737
Status:
COMPLETED
Last Update Posted:
2016-09-16
First Post:
2007-01-22
Brief Title:
Assess Efficacy Immune Response Safety of 2 Doses of Oral Live Attenuated HRV Vaccine in Healthy Infants
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A Study to Assess the Efficacy Immunogenicity and Safety of Two Doses of Oral Live Attenuated Human Rotavirus HRV Vaccine Rotarix in Healthy Infants
Status:
COMPLETED
Status Verified Date:
2016-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To assess the efficacy immune response and safety of the oral live attenuated HRV vaccine Rotarix in healthy infants approximately 2 months of age and previously uninfected with human rotavirus
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None